Sumit Jadhav’s Post

On November 16, 1914, a significant milestone in the history of science and medicine was achieved when the first successful blood transfusion using blood from a human was performed by Dr. Reuben Ottenberg at the Montefiore Medical Center in New York City. This groundbreaking event marked a turning point in medical practice, laying the groundwork for modern transfusion medicine and saving countless lives in the years to come. Before this historic transfusion, attempts at blood transfusion were often met with complications and misunderstandings about blood types. The concept of blood compatibility was not well understood, which led to significant risks, including severe immune reactions and side effects. Dr. Ottenberg’s work was paving the way toward safer transfusions. Dr. Ottenberg carefully studied blood types, using the ABO blood grouping system discovered by Karl Landsteiner in 1901, which enabled medical professionals to understand the importance of matching blood types for transfusions. The successful transfusion not only saved the life of a patient but also established critical protocols for conducting future blood transfusions, emphasizing the need for careful screening and testing. This success prompted further research into blood types and transfusion practices, contributing to advancements in hematology and emergency medicine. By World War I, blood transfusions became a standard practice on the battlefield, significantly improving survival rates for injured soldiers and further validating the importance of Ottenberg's work. As we reflect on this important moment from November 16, we celebrate the innovations in medical science that have allowed for the safe and effective transfusion of blood, recognizing the lives saved through this vital medical procedure. It serves as a testament to the power of research, trial, and perseverance in advancing healthcare. What do you think are the most important developments in medical science that have shaped patient care today, and how can we continue to innovate and improve medical practices for future generations? #MedicalHistory #BloodTransfusion #Innovation #ReubenOttenberg #Hematology #Science #Healthcare

RainMed is collaborating with Sino Medical in the PIONEER IV trial, a prospective randomized trial that will be conducted in 30 hospitals across Europe with 2,540 patients and involves patients with various types of coronary heart disease, including acute heart disease, chronic heart disease, or vascular stenosis. Eligible patients will undergo a non-invasive physiological vascular screening process to determine which vessels require stenting. RainMed's caFFR technology will be used in this clinical trial together with Medis Medical Imaging's QFR as a non-invasive physiological detection technology. The trial is sponsored by the National University of Ireland Galway and centrally coordinated by the University's Advanced Imaging and Core Laboratory CORRIB Research Center, and led by Patrick W. Serruys, Senior Professor of Interventional Medicine and Innovation, and William Wijns, Science Foundation Ireland Professor of Interventional Cardiology. The trial is currently underway, and RainMed's caFFR technology has been installed and enrolled in multiple centers. For more information about the PIONEER IV study, please visit www.clinicaltrials.gov, identifier: NCT04923191. #RainMed #caFRR #Clinicaltrials

A roadmap for precision medicine It was my pleasure to attend the Children’s Hospital of Philadelphia conference titled "Going Down the DIRT Path: From Mechanism to Treatment of Immune Dysregulation Conference." It is really consolidated for my personal belief of how we look in the coming years for how the practice of medicine should be changed, looking back to the importance of integrating basic science in clinical practice. No doubt, with the recent studies on genetic mapping and signatures for the patient and the specific interventions that made a significant impact on diagnostic and management outcomes,. The conference was well organised, and the content took you over the systematic approach with well-developed critical thinking and clinical reasoning on the way of diagnosing immuno-dysrequlation whenever it’s happened with different titles. Same paradigm was reflected in a well written paper recently I passed through by Joseph Stevens (Biological basis of critical illness subclasses: from the bedside to the bench and back again) a state of art article explaining the importance of understanding the adaptive immune response resulting in a systemic inflammatory response syndrome (SIRS) followed by a compensatory anti-inflammatory response (CARS) syndrome, it was a challenge of identifyincation however the Precision medicine address these challenges by identifying subsets of critically ill patients based on shared features including clinical, laboratory, biomarker,hence timing of certain immunosuppressants,immunomdulator and others will adapt the pathophysiology of the body and give better outcomes,those patients like ARDS ,Severe Asthma,encephalopathy and others critical illness.

How is Cardiovascular CT shaping clinical practice? Our latest publication delves into recent advancements and innovative applications of Cardiovascular CT (CCT). This review provides a clinically-focused overview of the latest studies, highlighting their impact on the evolving landscape of cardiovascular medicine. Special thanks to our international co-authors for their valuable insights, which contributed to a comprehensive discussion on the expanded, yet strategic and purposeful, use of CCT in modern cardiovascular care. Dr James Otton Tarique Hussain Tayaba Miah Andreas Schuster https://lnkd.in/e3nxxG3V #YesCCT

Late-Breakers AMERICAN COLLEGE of CARDIOLOGY ACC 2024 ATLANTA 6-8 Avril Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials IVUS-ACS: Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes Ultimate DAPT: One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes RELIEVE-HF: A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients With HFrEF and HFpEF ORBITA-COSMIC: Coronary Sinus Reducer for the Treatment of Refractory Angina EMPACT-MI: Empagliflozin After Acute Myocardial Infarction REDUCE-AMI: Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction SMART: Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli DEDICATE-DZHK6: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk PERFORM-TAVR: Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement PREVENT: Preventive PCI or Medical Therapy Alone for Atherosclerotic Coronary Vulnerable Plaques FULL REVASC: Ffr-guidance for complete non-culprit REVASCularization DanGer Shock: Danish-German cardiogenic shock trial TARGET BP I: Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs https://lnkd.in/eBCNUD_a

Dallas campus medical director and a national leader in CV research, Robert C. Stoler MD, FACC, FSCAI, is one of the lead authors on the JAMA Network March 9th article Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis. The article provides an overview of AGENT IDE, a multicenter randomized trial of 600 patients designed to evaluate paclitaxel-coated balloon as a treatment strategy for in-stent restenosis. Findings indicate that target lesion failure was significantly lower in the paclitaxel-coated balloon group. Read the key points. https://lnkd.in/exvdSb-B

My first paper is published! 👏 Excited to announce that our systematic review and meta-analysis on "The impact of frailty and surgical risk on health-related quality of life after TAVI" has been published in Journal of Cardiovascular Development and Disease. In our study we explored the impact of frailty and surgical risk on health-related quality of life (HrQoL) in patients undergoing transcatheter aortic valve implantation (TAVI). Our study reveals a clinically significant HrQoL benefit in the general TAVI population, in the high to extreme surgical risk patients and in the intermediate surgical risk patients at 1 year after TAVI. However, the patients with high to extreme surgical risk reveal an even greater HrQoL benefit when compared to the patients at intermediate surgical risk. In addition, our study also reveals a HrQoL benefit in frail patients from the randomized trials, equal to the benefit of the general TAVI population. Many thanks to my multidisciplinary research team for their unwavering support and guidance during this first chapter of my PhD! Bart Spaetgens Wolfgang Buhre Bart Maesen Dianne de Korte-de Boer Sander van Kuijk Arnoud van 't Hof Jan Uwe Schreiber Maastricht UMC+ Maastricht University Cardiovascular Research Institute Maastricht (CARIM) #cardiovascular #research #cardiacanesthesia #JCDD #maastrichtuniversity #MUMC #PhD #qualityoflife #TAVI

A very important and timely scientific statement from the hotter side of America on device based therapy for patients with Heart failure Alongside pharmacological advancements, device-based therapies have shown efficacy in HF management, including implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT). More recently, devices such as cardiac contractility modulation (CCM) and baroreflex activation therapy (BAT) have been approved by the FDA, although they lack comprehensive guideline recommendations. This scientific statement outlines the unmet needs in chronic HF, reviews contemporary data and provides a framework for integrating novel device-based therapies into current clinical workflows. It emphasizes the importance of early diagnosis and phenotyping, proper patient stratification and a personalized approach to combining pharmacological and device therapies. The document also highlights the need for further research into device interactions and patient selection to optimize outcomes, while recognizing the need for a more integrated approach to treatment so as to address the unmet needs and residual risks in HF management

Should you use base excess in the classification of hypovolemic shock? Over a decade ago, a landmark publication claimed that base excess outperformed traditional vital signs for the identification of trauma patients requiring blood transfusion. Subsequently, base excess was included in the ATLS classification of hypovolemic shock and has been widely embraced as a laboratory standard for acute hypovolemia in emergency medicine and critical care. In this study we critically reappraised the original evidence. We performed a fully reproducible simulation of the original publication’s data. By applying the same methodology to data with pre-set correlations, we show that the methodology contains a systematic bias in favour of base excess. It is physiologically reasonable to include a metabolic parameter to classify hypovolemic shock, but robust research is needed and other parameters should be considered. Read our recent publication at: https://lnkd.in/emrykqNV Tomas Heldeweg, Julius Stohlmann, Rohan Boer, Drs., Pedro Jorge, Patrick Schober

🔎 TCT 2024: Advancing Interventional Cardiovascular Medicine #TCT2024 gathered over 10,000 participants in Washington, D.C., to explore the latest in interventional cardiovascular medicine. The conference featured 161 sessions, 33 live cases, and 1,400+ faculty, providing a platform for innovation and scientific exchange. Key highlights included: 📌 11 late-breaking clinical trials and 15 late-breaking science presentations, with a focus on early intervention strategies in studies such as EARLY TAVR and EVOLVED. 📌 The TCT Medtech Innovation Forum, which delved into global market trends, regulatory updates, and AI’s role in healthcare. Notably, Symbiosis won the Shark Tank Innovation Competition for its adjustable transcatheter mitral valve replacement solution, a significant step forward in optimizing procedural outcomes. 📌 Discussions on advancements in coronary and valve interventions, highlighting the latest device technologies. KCRI had a strong presence, with several managed studies featured. Beyond our role as the angiographic core laboratory for the TESLA Registry, KCRI’s management of the DANGER SHOCK trial was a focal point in multiple sessions. This included in-depth discussions and subanalyses that are shaping the understanding of cardiogenic shock management. We are proud to provide evidence and contribute to innovation. #ClinicalResearch #Cardiology #TCT2024 #KCRI #TESLARegistry #DANGERShock #Innovation